{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:44:37Z","timestamp":1790419477676,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,6,15]]},"abstract":"<jats:p>Immune-mediated, acquired pure red cell aplasia (PRCA) is a rare disorder frequently associated with other autoimmune phenomena. Conventional immunosuppressive treatment is often unsatisfactory. Rituximab is a monoclonal antibody against the CD20 antigen, highly effective for in vivo B-cell depletion. An 18-month-old girl with both severe PRCA and autoimmune hemolytic anemia, refractory to immunosuppressive treatment, received 2 doses of rituximab, 375 mg\/m2 per week. The drug was well tolerated. After anti-CD20 therapy, substitutive treatment with intravenous immunoglobulin was started. The treatment resulted in marked depletion of B cells; a striking rise in reticulocyte count ensued, with increasing hemoglobin levels, finally leading to transfusion independence. The child is now 5 months off-therapy, with normal hemoglobin and reticulocyte levels. This case suggests a role of anti-CD20 monoclonal antibody for treatment of patients with antibody-mediated hematologic disorders.<\/jats:p>","DOI":"10.1182\/blood.v97.12.3995","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:47Z","timestamp":1027759607000},"page":"3995-3997","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia"],"prefix":"10.1182","volume":"97","author":[{"given":"Marco","family":"Zecca","sequence":"first","affiliation":[{"name":"From Pediatric Hematology\/Oncology, IRCCS Policlinico San Matteo, University of Pavia, Italy, and the Department of Pediatrics, University of Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"De Stefano","sequence":"additional","affiliation":[{"name":"From Pediatric Hematology\/Oncology, IRCCS Policlinico San Matteo, University of Pavia, Italy, and the Department of Pediatrics, University of Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Nobili","sequence":"additional","affiliation":[{"name":"From Pediatric Hematology\/Oncology, IRCCS Policlinico San Matteo, University of Pavia, Italy, and the Department of Pediatrics, University of Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"From Pediatric Hematology\/Oncology, IRCCS Policlinico San Matteo, University of Pavia, Italy, and the Department of Pediatrics, University of Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300071867300_B1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2141.1993.tb03163.x","article-title":"Pure red cell aplasia in childhood and adolescence: pathogenesis and approaches to diagnosis.","volume":"85","author":"Freedman","year":"1993","journal-title":"Br J Haematol."},{"key":"2020021300071867300_B2","first-page":"216","volume-title":"Bone marrow failure syndromes. In Nathan DG, Oski FA, eds. Hematology of infancy and childhood.","author":"Alter","year":"1993"},{"key":"2020021300071867300_B3","first-page":"448","article-title":"Pure red cell aplasia. In Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds.","volume-title":"Williams Hematology.","author":"Erslev","year":"1995"},{"key":"2020021300071867300_B4","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1136\/bmj.2.6100.1444","article-title":"Reticulocytopenia and \u201cabsence\u201d of red cell autoantibodies in immune haemolytic anaemia.","volume":"2","author":"Hegde","year":"1977","journal-title":"Br Med J."},{"key":"2020021300071867300_B5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021300071867300_B6"},{"key":"2020021300071867300_B7","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood."},{"key":"2020021300071867300_B8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody.","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol."},{"key":"2020021300071867300_B9","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90 [abstr 349]","author":"Maloney","year":"1997","journal-title":"Blood."},{"key":"2020021300071867300_B10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021300071867300_B11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI113071","article-title":"Detective \u201cin vitro\u201d growth of hemopoietic progenitor cells CFU-GEMM, CFU-Mk, BFU-E and CFU-GM in the acquired immunodeficiency syndrome (AIDS).","volume":"80","author":"CarloStella","year":"1987","journal-title":"J Clin Invest."},{"key":"2020021300071867300_B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-133-4-200008150-00011","article-title":"Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease.","volume":"133","author":"Ratanatharathorn","year":"2000","journal-title":"Ann Intern Med."},{"key":"2020021300071867300_B13","first-page":"596a","article-title":"Rituxan in the treatment of autoimmune hemolytic anemia (AIHA).","volume":"96(suppl 1)","author":"Lee","year":"2000","journal-title":"Blood."},{"key":"2020021300071867300_B14","first-page":"253a","article-title":"Treatment with anti-CD20 antibodies of patients with autoimmune thrombocytopenia with or without hemolytic anemia; worsening in the hemoglobin level.","volume":"96(suppl 1)","author":"Grossi","year":"2000","journal-title":"Blood."},{"key":"2020021300071867300_B15","first-page":"730a","article-title":"Rituxan (Rituximab) therapy for chronic cold agglutinin disease.","volume":"96(suppl 1)","author":"Berenstein","year":"2000","journal-title":"Blood."},{"key":"2020021300071867300_B16","volume-title":"Rituxan: product profile and guide to clinical use.","year":"1998"},{"key":"2020021300071867300_B17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving Rituximab.","volume":"344","author":"Dervite","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021300071867300_B18","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab.","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/12\/3995\/1675361\/h8120103995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/12\/3995\/1675361\/h8120103995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:07:26Z","timestamp":1581552446000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/12\/3995\/107255\/AntiCD20-monoclonal-antibody-for-the-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,15]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.12.3995","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6,15]]}}}